Explore Intellia Therapeutics, Inc.'s outlook after Phase 3 trial concerns. See how FDA decisions may impact CRISPR therapy ...
A new paper from the University of Kansas overturns the idea that a "risk gene" carried by millions of people worldwide ...
A new paper from the University of Kansas overturns the idea that a "risk gene" carried by millions of people worldwide ...
Developed by UCL spinout Autolus, Aucatzyl will be launched imminently across England and Wales. A UK-developed cell therapy ...
ToolGen and GenEditBio have previously collaborated on GEB-200 and completed a proof-of-concept study in non-human primates. As they advance GEB-200 through clinical trials, the companies said they ...
Integrates ToolGen's best-in-class CRISPR-Cas9 platform with GenEditBio's industry-leading lipid nanoparticle (LNP) delivery ...
Integrates ToolGen's best-in-class CRISPR-Cas9 platform with GenEditBio's industry-leading lipid nanoparticle (LNP) delivery technologyPursues a 'once-and-done' treatment paradigm for diseases with ...
The immune system plays a crucial role in fighting tumors and metastases. Consequently, it is decisive to conduct cancer research in mouse models with an immune system that is as natural as possible – ...
Hosts David and Gina explore how scientists over the centuries unlocked the ability to edit our genes ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback